Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals is a global healthcare company focused on the development and commercialization of differentiated healthcare solutions based on its patented stabilized hypochlorous acid (HOCl) technology.

Our portfolio includes products for a broad range of applications, including wound care and dermatology, with solutions designed to support the management of conditions such as eczema, atopic dermatitis, acne, scars and eyelid-related conditions. Our European medical-device portfolio is developed and marketed in accordance with applicable MDR requirements.

Sonoma’s proprietary technology combines anti-inflammatory and antimicrobial properties with a pH-neutral, non-toxic and non-cytotoxic profile. It is designed to support effective treatment without damaging healthy tissue and without contributing to bacterial resistance.

Our products support the body’s natural healing processes and are backed by clinical evidence demonstrating benefits across a range of applications, including wound management, reduction of microbial burden, inflammation, itching, pain and scarring.

Sonoma Pharmaceuticals works with established commercial partners in more than 21 European countries and over 60 countries worldwide. Through these partnerships, we bring differentiated, evidence-based and patent-protected products to patients and healthcare professionals across international markets.

As part of our continued international expansion, we are seeking experienced partners in selected markets.

If your organization is interested in licensing Sonoma’s patented Microcyn® Technology or distributing one or more products from our portfolio, we would welcome the opportunity to explore a potential partnership.